© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
FDA Label Update Positions Inclisiran as First-Line Monotherapy for Hypercholesterolemia
August 01, 2025
Inclisiran can now be used without a background statin, as an adjunct to changes in diet and physical activity for reduction of LDL-C in hypercholesterolemia.
Lecanemab Shows Sustained Benefit at 4 Years in Early Alzheimer Disease: AAIC 2025
August 01, 2025
Four-year data show lecanemab slows clinical decline in early Alzheimer disease and maintains a consistent safety profile.
Tirzepatide Proves Noninferiority With Dulaglutide for MACE in Lilly's Landmark Incretin Face-Off
August 01, 2025
In the SURPASS-CVOT trial, tirzepatide reduced MACE-3 by 8% and all-cause mortality by 16% compared with dulaglutide, while also reducing HbA1c and weight.
New Option for Chronic Hand Eczema Gets FDA Green Light: Daily Dose
August 01, 2025
Your daily dose of the clinical news you may have missed.
New Data Highlight Significant Challenges to Managing CAH: Daily Dose
August 01, 2025
Your daily dose of the clinical news you may have missed.
Amesh Adalja, MD, on How to Defuse Vaccine Safety Concerns Without Derailing the Visit
July 31, 2025
Dr Adalja offers evidence-based strategies to address patient concerns about aluminum and thimerosal in vaccines.
FDA Grants Fast Track Designation to Rezpegaldesleukin for Alopecia Areata
July 31, 2025
FDA grants Fast Track designation to rezpegaldesleukin for severe alopecia areata, highlighting its potential to meet critical treatment needs.
Maternal Depression Found to Disrupt Emotional Responsiveness, Infant Care: Daily Dose
July 31, 2025
Your daily dose of the clinical news you may have missed.
Amesh Adalja, MD, Breaks Down 2025 Vaccine Policy Shifts for Primary Care
July 30, 2025
Infectious disease expert Amesh Adalja, MD, outlines the biggest vaccine policy shifts of 2025, including changes to COVID-19 and flu vaccine recommendations.
Donanemab Showed Sustained Cognitive Benefit Over 3 Years in Early Alzheimer Disease
July 30, 2025
Three-year follow-up data from the TRAILBLAZER-ALZ 2 extension trial supported early initiation and limited-duration dosing.